ERRATUM

Erratum to: Evaluation and Treatment of Gout as a Chronic Disease

Fernando Perez-Ruiz · Ana Maria Herrero-Beites

© Springer Healthcare 2012

Erratum to: Perez-Ruiz F, Herrero-Beites AM. Evaluation and Treatment of Gout as a Chronic Disease. Adv Ther. 2012;29(11):935–46.

The authors of the above-mentioned paper would like to make the following adjustments to their article.

In the published Fig. 1, the values in the allopurinol 300 mg once daily and febuxostat 120 mg once daily columns are incorrect. The correct values are detailed in the corrected Fig. 1, below.

Fig. 1 Efficacy and effectiveness of ULDs in phase 3/4, double-blind, randomized trials. Head to head comparisons only for same references, otherwise indirect comparisons. Data of outcomes from final visit, except pegloticase: week 11 for efficacy and overall combined 3–6 months for effectiveness. Data obtained from [27–29]. *Allo 300/600* allopurinol 300/600 mg once daily, *Bnz 100/200* benzbromarone 100/200 mg/day, *Feb 80/120* febuxostat 80/120 mg once daily, *Peg 8 cow* pegloticase 8 mg biweekly, *ULD* urate-lowering treatment

The authors thank Springer Healthcare for publishing the correction.